# A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache

> **NCT02797951** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 165 (actual)

## Conditions studied

- Episodic Cluster Headache
- Chronic Cluster Headache

## Interventions

- **DRUG:** Galcanezumab

## Key facts

- **NCT ID:** NCT02797951
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-13
- **Primary completion:** 2021-01-21
- **Final completion:** 2021-01-21
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2022-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02797951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02797951, "A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02797951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*